Moderna (NASDAQ:MRNA) Issues Earnings Results

Moderna (NASDAQ:MRNA) announced its quarterly earnings data on Friday. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06, FiscalAI reports. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The business had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter in the previous year, the business earned ($2.13) earnings per share. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year.

Here are the key takeaways from Moderna’s conference call:

• 2026 revenue and cost outlook improved: Moderna reiterated revenue growth of up to 10% and lowered its full-year cost-of-sales and R&D forecasts by $100 million each, while reducing expected cash costs by $200 million to approximately $4 billion.
• Flu vaccine advances toward potential approval: mRNA-1010 received a unanimous positive recommendation from the FDA advisory committee, with a U.S. PDUFA decision expected August 5 and regulatory reviews ongoing in Europe, Canada, and Australia.
• mNEXSPIKE showed strong initial commercial traction: The COVID vaccine captured approximately 24% of the U.S. retail market in its first season and about 34% among adults aged 65 and older, supported by encouraging real-world effectiveness data against hospitalization.
• Norovirus vaccine development faces a delay: mRNA-1403 did not meet statistical criteria for early success at its interim analysis, requiring enrollment of an additional cohort and another seasonal period to collect sufficient cases; the trial remains blinded.
• Pipeline milestones remain active: Moderna expects an interim analysis for the fully enrolled phase III intismeran melanoma study in the second half of 2026 and data from its registrational propionic acidemia study in the fourth quarter, while expanding oncology programs into Lynch syndrome and solid tumors.

Moderna Price Performance

NASDAQ MRNA traded down $3.10 on Friday, reaching $54.82. The company had a trading volume of 7,754,397 shares, compared to its average volume of 8,851,560. The company has a quick ratio of 2.35, a current ratio of 2.41 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $21.75 billion, a PE ratio of -6.73 and a beta of 0.94. The firm’s 50 day moving average price is $59.21 and its 200 day moving average price is $52.50. Moderna has a 12 month low of $22.28 and a 12 month high of $85.60.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported second-quarter EPS of -$1.97, better than the roughly -$2.03 consensus and an improvement from -$2.13 a year earlier. Revenue was approximately $145 million, while management reiterated its plan for up to 10% revenue growth in 2026. Moderna Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: The company improved its 2026 operating-expense outlook by about $200 million and now expects year-end cash of $4.7 billion to $5.2 billion, supporting its effort to reduce cash burn. Moderna also faces a potentially important catalyst on August 5, when regulators are scheduled to decide on its seasonal flu vaccine candidate, mFLUSIVA. Moderna Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Trading activity showed elevated interest in Moderna call options, with 82,913 contracts acquired versus a typical daily volume of 48,590. This may indicate speculative bullish positioning, but options activity alone does not establish a sustained change in investor sentiment.
• Negative Sentiment: Moderna’s Phase 3 mRNA-1403 norovirus vaccine trial did not meet the statistical criteria for early success at its interim analysis. The company plans to add another participant cohort, extending the trial into a fourth season and delaying clarity on a potential commercial opportunity. Moderna Adds New Cohort to Phase III Vaccine Trial
• Negative Sentiment: Investors remain concerned about Moderna’s dependence on declining COVID-19 vaccine sales. Although the quarterly loss narrowed, the company still posted a GAAP net loss of about $782 million, and reports characterized revenue as weaker than Wall Street expected. The norovirus setback therefore outweighed the earnings and cost-control improvements. Moderna Misses Quarterly Revenue Estimates on COVID Vaccine Weakness

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president owned 1,483,848 shares in the company, valued at $76,225,271.76. This trade represents a 3.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider directly owned 67,468 shares in the company, valued at $3,373,400. This trade represents a 4.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 119,406 shares of company stock valued at $5,928,762 in the last 90 days. Insiders own 10.80% of the company’s stock.

Institutional Trading of Moderna

Several hedge funds have recently made changes to their positions in the business. Invesco Ltd. raised its holdings in Moderna by 15.7% during the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock valued at $212,223,000 after buying an additional 1,115,131 shares during the period. Theleme Partners LLP increased its position in Moderna by 8.6% during the second quarter. Theleme Partners LLP now owns 7,868,810 shares of the company’s stock valued at $217,100,000 after acquiring an additional 626,420 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Moderna by 7.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,621,558 shares of the company’s stock valued at $136,290,000 after acquiring an additional 309,126 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in shares of Moderna in the fourth quarter valued at $95,209,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of Moderna by 123.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,788,951 shares of the company’s stock valued at $52,775,000 after acquiring an additional 987,312 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on MRNA. Piper Sandler lifted their price target on Moderna from $69.00 to $77.00 and gave the stock an “overweight” rating in a research report on Friday, June 26th. Barclays upped their price target on Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a report on Thursday, April 2nd. Morgan Stanley increased their price objective on Moderna from $33.00 to $39.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 8th. The Goldman Sachs Group lifted their target price on shares of Moderna from $49.00 to $67.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 21st. Finally, Wolfe Research reiterated an “underperform” rating and issued a $25.00 price objective on shares of Moderna in a research note on Monday, July 20th. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $40.00.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.